Müzes G, Deák G, Láng I, Nékám K, Niederland V, Fehér J
Semmelweis Orvostudományi Egyetem, II. Belgyógyászati Klinika, Budapest.
Orv Hetil. 1990 Apr 22;131(16):863-6.
A double blind study. Antioxidant and antiperoxidative effects of the free radical scavenger agent silymarin (Legalon) were investigated in patients with chronic alcoholic liver disease in a double blind clinical trial. Six month treatment (at a daily dose of 420 mg) with silymarin significantly enhanced the originally low superoxide dismutase activity of erythrocytes and lymphocytes and also restored the diminished superoxide dismutase expression on lymphocytes as measured by flow-cytofluorimetry. In addition, silymarin therapy markedly increased the serum level of ree--SH groups and the activity of glutathione peroxidase. In contrast, a considerable fall in serum malondialdehyde concentration was detected in patients having received silymarin. However, in case of placebo-treated patients the above mentioned parameters of antioxidant defense system and lipid peroxidation failed to change significantly. These data indirectly suggest that antioxidant, antiperoxidative effects might be important factors in the mechanism of hepatoprotective action of silymarin.
一项双盲研究。在一项双盲临床试验中，对自由基清除剂水飞蓟宾（利加隆）在慢性酒精性肝病患者中的抗氧化和抗过氧化作用进行了研究。水飞蓟宾治疗六个月（每日剂量420毫克）可显著提高红细胞和淋巴细胞原本较低的超氧化物歧化酶活性，并通过流式细胞荧光测定法使淋巴细胞上减少的超氧化物歧化酶表达恢复正常。此外，水飞蓟宾治疗可显著提高血清游离巯基水平和谷胱甘肽过氧化物酶活性。相反，接受水飞蓟宾治疗的患者血清丙二醛浓度显著下降。然而，在接受安慰剂治疗的患者中，上述抗氧化防御系统和脂质过氧化参数未发生显著变化。这些数据间接表明，抗氧化、抗过氧化作用可能是水飞蓟宾肝保护作用机制中的重要因素。
